How important is transfusion avoidance in 2013?

Nephrology Dialysis Transplantation

Volumn 28, Issue 5, 2013, Pages 1092-1099

  MacDougall, Iain C ^a   Obrador, Gregorio T ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSIDAD PANAMERICANA   (Mexico)

Author keywords

anaemia; ESA therapy; HLA sensitization; transfusions; transplantation

Indexed keywords

ANTIANEMIC AGENT; IMMUNOGLOBULIN E; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; DISEASE TRANSMISSION; FEMALE; HEMODIALYSIS; HLA MATCHING; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK REDUCTION;

ANAEMIA; ESA THERAPY; HLA SENSITIZATION; TRANSFUSIONS; TRANSPLANTATION;

ANEMIA; BLOOD TRANSFUSION; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84877940214     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs575     Document Type: Article

References (54)

1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int 1985; 28: 1-5
2. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National, Institutes of Health, National Institute of Diabetes and Digestive and Kidney, Diseases, 2009
3. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
4. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
5. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
6. Pfeffer MA, Burdmann EA, Chen C-Y et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
7. Collins AJ. Presentation at the National Kidney Foundation meeting, May 2012
8. Robinson BM. Presentation at the National Kidney Foundation meeting, May 2012
9. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007; 370: 415-426
10. UK Serious Hazards of Transfusion (SHOT). Annual Report 2010. http://www.shotuk.org/wp-content/uploads/2011/07/SHOT-2010-Summary1.pdf (23 September 2012, date last accessed)
11. FDA Annual Summary for Fiscal Year 2010. Fatalities reported to FDA following blood collection and transfusion. http://www.fda.gov/downloads/ BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/ TransfusionDonationFatalities/UCM254860.pdf (23 September 2012, date last accessed)
12. Revillard JP, Betuel H. Circulating antibodies in allograft recipients. Adv Nephrol Necker Hosp 1975; 5: 257-281
13. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med 1978; 299: 799-803
14. Cecka JM. The transfusion effect. Clin Transplant 1987: 287-301
15. Opelz G, Terasaki PI. Poor kidney-transplant survival in recipients with frozen blood transfusions or no transfusions. Lancet 1974; 2: 696-698
16. Feduska NJ, Vincenti F, Amend WJ, Jr et al. Do blood transfusions enhance the possibility of a compatible transplant? Transplantation 1979; 27: 35-38
17. Corry RJ, West JC, Hunsicker LG et al. Effect of timing of administration and quantity of blood transfusion on cadaver renal transplant survival. Transplantation 1980; 30: 425-428
18. Frisk B, Brynger H, Wedel N et al. Blood transfusion in cadaveric renal Transplantation-a prospective study. Scand J Urol Nephrol Suppl 1981; 64: 100-105
19. Opelz G Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplantation 1985; 40: 240-243
20. Carpenter CB. Blood transfusion effects in kidney transplantation. Yale J Biol Med 1990; 63: 435-443
21. Opelz G, Vanrenterghem Y, Kirste G et al. Prospective evaluation of pre-transplant blood transfusions in cadaver kidney recipients. Transplantation 1997; 63: 964-967
22. Vella JP, O'Neill D, Atkins N et al. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 1998; 13: 2027-2032
23. Grimm PC, Sinai-Trieman L, Sekiya NM et al. Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 1990; 38: 12-18
24. Deierhoi MH, Barger BO, Hudson SL et al. The effect of erythropoietin and blood transfusions on highly sensitized patients on a single cadaver renal allograft waiting list. Transplantation 1992; 53: 363-368
25. Fehrman-Ekholm I, Sumitran-Karuppan S. Antibodies in alloim-munized uraemic patients treated with recombinant erythropoietin. Transplant Int 1994; 7: S290-S293
26. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
27. Reed A, Pirsch J, Armbrust MJ et al. Multivariate analysis of donor-specific versus random transfusion protocols in haplo-identical living-related transplants. Transplantation 1991; 51: 382-384
28. Vanrenterghem Y, Waer M, Roels L et al. A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. Leuven Collaborative Group for Transplantation. Transplant Int 1994; 7: S243-S246
29. Opelz G, Graver B, Mickey MR et al. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 1981; 32: 177-183
30. Christiaans MH, van Hooff JP, Nieman F et al. HLA-DR matched transfusions: development of donor-specific T-and B-cell antibodies and renal allograft outcome. Transplantation 1999; 67: 1029-1035
31. Cecka JM, Cicciarelli J, Mickey MR et al. Blood transfusions and HLA matching-an either/or situation in cadaveric renal transplantation. Transplantation 1988; 45: 81-86
32. Pfaff WW, Howard RJ, Scornik JC et al. Incidental and purposeful random donor blood transfusion. Sensitization and transplantation. Transplantation 1989; 47: 130-133
33. Sanfilippo F, Vaughn WK, Bollinger RR et al. Comparative effects of pregnancy, transfusion, and prior graft rejection on sensitiz-ation and renal transplant results. Transplantation 1982; 34: 360-366
34. US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011.
35. Goodnough LT. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 2000; 40: 1522-1527
36. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001; 41: 691-712
37. Uhlmann EJ, Isgriggs E, Wallhermfechtel M et al. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41: 997-1000
38. Dzik WH, Anderson JK, O'Neill EM et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42: 1114-1122
39. Ratko TA, Cummings JP, Oberman HA et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001; 41: 1310-1319
40. Cleemput I, Leys M, Ramaekers D et al. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction. Int J Technol Assess Health Care 2006; 22: 403-407
41. Scornik JC, Ireland JE, Howard RJ et al. Role of regular and leukocyte-free blood transfusions in the generation of broad sensitiz-ation. Transplantation 1984; 38: 594-598
42. Sanfilippo FP, Bollinger RR, MacQueen JM et al. A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients. Transfusion 1985; 25: 116-119
43. Karpinski M, Pochinco D, Dembinski I et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818-824
44. Everett ET, Kao KJ, Scornik JC. Class I HLA molecules on human erythrocytes. Quantitation and transfusion effects. Transplantation 1987; 44: 123-129
45. Port F, Wolfe R, Mauger E et al. Comparison of survival probabilities for dialysis patients versus cadaveric renal transplant recipients. JAMA 1993; 270: 1339-1343
46. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005; 16: 1859-1865
47. Lefaucheur C, Loupy A, Hill GS et al. Pre-existing donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406
48. Lawler EV, Bradbury BD, Fonda JR et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol 2010; 5: 667-672
49. Lawler EV, Gagnon DR, Fink J et al. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. Nephrol Dial Transplant 2010; 25: 2237-2244
50. Seliger S, Fox KM, Gandra SR et al. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol 2010; 5: 882-888
51. Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417
52. Murphy MF, Wallington TB, Kelsey P et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001; 113: 24-31
53. The Cochrane Library. Avoiding unnecessary blood transfusion. http://www.thecochranelibrary.com/details/collection/2116331/ Avoiding-unnecessary-blood-transfusion.html (18 November 2012, date last accessed)
54. KDIGO Anemia Guideline Work Group. http://www.kdigo.org/clinical- practice-guidelines/pdf/KDIGO-Anemia%20GL.pdf (23 September 2012, date last accessed)